Olympus agrees $270m BioProtect buyout to expand prostate cancer offerings

BioProtect’s lead product is a spacer system designed to protect healthy tissues during radiation therapies for prostate cancer treatment. BioProtect’s lead product is a spacer system designed to protect healthy tissues during radiation therapies for prostate cancer treatment. The acquisition of BioProtect aligns with Olympus’s aims to expand its oncology and urology care provision. Credit: JHVEPhoto / Shutterstock.com Olympus has agreed to acquire BioProtect in a $270m deal, giving the company a commercial device that will help expand its prostate cancer care provision. Israel-based BioProtect’s lead product is Balloon Spacer, a system designed to provide consistent spacing between the prostate…

Source: Medical Device Network